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PEMBANGUNAN DAN PENCIRIAN SISTEM SUPOSITORI BIOADHESIF 
PELEPASAN CEPAT YANG MENGANDUNGI NATRIUM DIKLOFENAK 
 
ABSTRAK 
 
Perpindahan dan migrasi supositori ke bahagian atas rektum merupakan suatu 
masalah biokeperolehan rektal yang lazim. Hanya drug yang diserap daripada 
supositori yang kekal di bahagian bawah rektal dapat dilindungi daripada 
tindakan berkesan metabolisme hati, manakala drug yang diserap daripada 
bahagian atas rektum pula akan mengalami metabolisme lintasan pertama. 
Suatu sistem supositori bioadhesif telah dibangunkan untuk mengekalkan 
kedudukan supositori pada bahagian bawah rektum dengan menggunakan 
dasar berminyak dan dasar larut-air, polimer hidrofilik Karbopol 934P (CP) dan 
Polivinilpirolidon K90 (PVP) serta natrium diklofenak (DcNa) sebagai drug 
model. Antara dasar-dasar supositori yang digunakan, ChocExa, Supercocofat 
HS dan Supercocofat menyerupai Cocoa Butter dengan ciri kekerasan dasar 
dan tempoh masa pelembutan dasar yang setara. Dasar-dasar ini juga 
mempunyai julat suhu peleburan, ciri bioadhesif serta profil pelepasan drug dua 
fasa yang hampir sama. CP merupakan polimer bioadhesif yang lebih baik 
daripada PVP. Kehadiran CP pada kandungan 2 % w/w mampu 
menyumbangkan sifat bioadhesif yang berkesan tetapi sebarang pertambahan 
kandungan CP boleh memanjangkan tempoh masa pelepasan DcNa dalam air 
suling lalu meningkatkan nilai konstan pelepasan drug awal, k1 serta 
meningkatkan masa untuk mencapai 50 % pelepasan drug, T50%. Dengan 
menggunakan ChocExa dalam kehadiran 2 % w/w CP serta DcNa, tiga jenis 
rekabentuk supositori telah dibangunkan, iaitu supositori konvensional, 
supositori berliang dan supositori dwi-lapisan. Tiga sediaan DcNa-CP juga 
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dinilai, iaitu campuran fizikal yang biasa, campuran berkisar dan sediaan granul 
basah. Supositori berliang and supositori dwi-lapisan mempunyai kadar 
pelepasan drug yang lebih cepat berbanding supositori konvensional. Kedua-
dua jenis supositori ini memiliki nilai kekerasan dasar yang lebih rendah serta 
tempoh masa pelembutan yang lebih cepat. Kesemua rekabentuk supositori 
yang mengandungi sediaan granul  DcNa-CP pula mempunyai kadar pelepasan 
yang lebih cepat berbanding campuran biasa dan campuran berkisar. Kedua-
dua profil FTIR dan DSC menunjukkan bahawa campuran berkisar DcNa-CP 
mempunyai profil perantaraan campuran biasa dan sediaan granul basah. 
Sebelum kajian in vivo dijalankan, suatu kaedah isokratik HPLC-UV yang 
mudah, spesifik dan sensitif telah divalidasi untuk tujuan kuantifikasi kandungan 
DcNa dalam plasma arnab. Kajian in vivo ke atas enam ekor arnab ini 
dijalankan berdasarkan kajian saling melintang tiga arah secara rawak. 
Supositori konvensional yang mengandungi sediaan granul DNa-CP (B) serta 
supositori berliang yang mengandungi sediaan granul DcNa-CP (C) telah 
dibandingkan dengan supositori konvensional yang mengandungi sediaan 
granul DcNa sahaja (A). Kadar dan jumlah penyerapan (AUC0-∞) serta nilai 
kepekatan maksimum plasma drug (Cmax) untuk formulasi B dan C didapati 
lebih tinggi secara signifikan berbanding formulasi A. Namun, nilai AUC0-∞ dan 
Cmax antara B dan C pula tidak berbeza secara signifikan, walaupun pada 
dasarnya nilai AUC0-∞ untuk formulasi C lebih tinggi daripada B. Secara 
kesimpulannya, suatu sistem supositori bioadhesif yang mampu ditempatkan di 
bahagian bawah rektum telah berjaya dibangunkan. Formulasi bioadhesif yang 
baru ini telah menunjukkan peningkatan biokeperolehan, sekaligus 
memperlihatkan kelebihan berbanding supositori konvensional. 
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DEVELOPMENT AND CHARACTERISATION OF FAST RELEASE 
BIOADHESIVE SUPPOSITORY SYSTEM CONTAINING  
DICLOFENAC SODIUM 
 
ABSTRACT 
 
The migration of suppository towards the upper rectum has always posed a 
problem in rectal bioavailability. Only drug absorbed from suppositories retained 
at the lower rectum can bypass the strongly metabolising liver, while drug 
absorbed from the upper rectum will experience first-pass metabolism. A 
bioadhesive suppository system was developed to localise the suppository onto 
the lower rectum by using fatty and water-soluble bases, hydrophilic polymers 
of Carbopol 934P (CP) and Polyvinylpyrrolidone K90 (PVP) and diclofenac 
sodium (DcNa) as model drug. Of all the bases evaluated, ChocExa, 
Supercocofat HS and Supercocofat resembled Cocoa Butter with comparable 
base hardness, short softening time and similar melting range, bioadhesive 
properties and biphasic drug release profiles. CP was a better bioadhesive 
polymer than PVP. The presence of CP at 2 % w/w yield considerable 
bioadhesive properties, but higher amount of CP prolonged DcNa release in 
distilled water with higher value of initial drug release constants, k1 and longer 
time to achieve 50 % of drug release (T50%). By employing CP at 2 % w/w in the 
ChocExa with DcNa, three different designs of suppositories, namely the 
conventional, hollow and double-layered suppositories were developed. Three 
different DcNa-CP mixtures were also evaluated, namely the physical mixture, 
co-grinding and wet granulations of DcNa-CP. The hollow and double-layered 
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suppositories released DcNa faster than the conventional design but with less 
base hardness values and shorter softening time. On the other hand, all 
designs of suppository containing granules of DcNa-CP were released faster 
than physical mixture and co-grinding of DcNa-CP. Both FTIR and DSC profiles 
of co-grinding preparation showed an intermediate profile of the physical 
mixture and granulation preparation. Prior to the in vivo study, a simple, specific 
and sensitive isocratic HPLC-UV method was validated for the quantification of 
DcNa in rabbit plasma. An in vivo study of three-way crossover design was 
performed on six rabbits for conventional suppository containing DcNa-CP 
granules (B) and hollow suppository containing DcNa-CP granules (C) in 
comparison to conventional suppository containing DcNa granules without CP 
(A).  The rate and extent of absorption (AUC0-∞) and the maximum drug plasma 
concentration (Cmax) for B and C were found to be significantly higher than A. 
However, the AUC0-∞ and Cmax between B and C were not significantly different, 
although the AUC0-∞ for C appeared to be higher than B. In conclusion, a 
bioadhesive suppository system that could be retained on the lower rectum was 
successfully prepared. The newly developed bioadhesive formulations resulted 
in an improvement of bioavailability, hence offering advantages over the 
conventional suppository. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Suppositories 
Suppositories are solid dosage forms that are used to administer medicine 
through the rectum, vagina and to a lesser extent, the urethra. The suppository 
is a very ancient form of medication, as is evidenced by its mention in the 
Hippocratic Oath (Ohmart, 1949; Plaxco et al., 1967). Suppositories were used 
in the ear and nose, but these uses are now obsolete. The forms of suppository 
in use today have been developed within the past hundred years. 
 
Generally, rectal suppositories are cylindrical, cone-shaped with a rounded 
apex or bullet-shaped. Such shapes have the advantage that when the widest 
part has been inserted the anal sphincter muscle presses the suppository 
forward into the rectum (Carter, 1975). In this way, the possibility of backward 
sliding is eliminated (Merkus, 1980). The shape and size of a suppository 
should assist easy insertion into the intended body orifice without causing 
undue distension, and once inserted, it must be retained for an appropriate 
period of time (Ansel, 1981). The rectal suppositories usually weigh about 2 g 
and are about 1 to 1.5 inches long. Infant and pediatric rectal suppositories 
weigh about half that of adult suppositories. 
 
Once inserted, the suppository base melts, softens or dissolves, distributing the 
medicaments it carries to the tissues of the region (Ansel, 1981). These 
medicaments may be intended for retention within the cavity for localised drug 
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effects, or to be absorbed for the exertion of systemic effects (Coben and 
Liebermann, 1986; Allen, 1995).  
 
Local applications, generally delivered within half an hour and last at least 4 
hours are frequently employed for laxative effects to relieve constipation or to 
counter pain, irritation, itching, infections and inflammation associated with 
hemorrhoids or other anorectal conditions. Drugs intended for local action are 
generally nonabsorbable, such as drugs for hemorrhoids, local anesthetics and 
antiseptics. The bases used for these drugs are slow in melting and slow in 
drug release, contrasted with suppository bases intended for systemic drugs. 
For systemic effects, the mucous membranes of the rectum permit the 
absorption of many soluble drugs, including antinauseants, antiasthmatics, 
antihistamines, antispasmodics, antibiotics, analgesics, tranquilizers and 
hormones (Carter, 1975; Ansel, 1981; Coben and Liebermann, 1986; Blaey and 
Tukker, 1988).  
 
 
1.2 Advantages of rectal administration 
The administration of drugs by routes other than orally has to be considered in 
several circumstances and for varying reasons. Arguments for choosing the 
rectal route for drug administration have, for decades, been presented by many 
workers (Carter, 1975; Moolenaar and Schoonen, 1980; Young et al., 1987; 
Blaey and Tukker, 1988; Choi et al., 1998a; Ryu et al., 1999; Uzunkaya and 
Bergisadi, 2003; Takatori et al., 2004): 
1. The patient is unable to make use of the oral route. This may be the case 
when the patient has an infliction of the gastrointestinal (GI) tract, is 
 3 
nauseous, or is postoperative (the patient may be unconscious or not able to 
ingest a drug orally), or when the patient is unable to swallow (jaw fractures, 
throat injury or advance diseases). Several categories of patients, namely 
infants, the very old or mentally disturbed may more easily use the rectal 
than the oral route. 
2. The drug under consideration is less suited for oral administration. This may 
be so in cases where oral intake results in gastric irritation or other GI side 
effects. Furthermore, drugs that can be easily destroyed or inactivated by 
the pH or enzymatic activity of the stomach or intestines need not be 
exposed to the destructive environments.  
3. The avoidance of the first pass hepatic elimination or metabolism. Drugs that 
are destroyed by portal circulation may bypass the liver through rectal 
absorption.  
4. Drugs with an unacceptable taste can be administered rectally without 
causing any inconvenience to the patients.  
5. The formulations into suppositories of certain drugs that are candidates for 
abuse (as in suicide) have also been considered.  
 
Apart from these apparent advantages, the rectal route also has several 
drawbacks. Depending on tradition, there are strong feelings of aversion in 
certain countries, such as in UK and USA to rectal administration of drugs, 
whereas there is complete acceptance in Eastern Europe. More rational points 
in this respect are slow and sometimes erratic and incomplete absorption that 
has been reported and the considerable inter and intrasubject variation. Also, 
the development of proctitis (inflammation of the rectum) has been reported 
 4 
(Blaey and Tukker, 1988). There are also problems with the large scale 
production of suppositories and a suitable shelf life achievement (the latter 
demanding stringent storage conditions).  
 
Thus, it can be concluded that rectal administration might not be the route of 
first choice, but in certain circumstances it can be of great advantage to the 
patients.  
 
 
1.3 Anatomy and physiology of rectum 
Rectal dosage forms are introduced in the body through the anus and are thus 
brought into contact to the most caudal part of the GI tract, namely the rectum. 
Anatomically, the rectum is part of the colon, forming the last 150-200 mm of the 
GI tract (Blaey and Tukker, 1988). Taking this into account a very limited 
absorption surface emerges.  
 
Under normal circumstances, the rectum does not have any active motility 
(Moolenaar and Schoonen, 1980) and filling provokes a defecation reflex which 
is under voluntary control. Usually the rectum is empty, containing only 2-3 mL 
of inert mucus fluid (pH 7-8) which has no enzymatic activity or buffer capacity. 
The mucus spreads over a total surface area of about 300 cm2 and 
approximately 100 µm thick over the organ (Blaey and Tukker, 1988).  
                 
The rectum can be subdivided into the anal canal and the ampulla, the latter 
forming approximately 80 % of the organ. It is separated from the outside world 
through a circular muscle, the anus. The rectum can be considered as a hollow 
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organ with a relatively flat wall surface, without villi and microvilli, and with only 
three major folds known as the rectal valves. The rectal wall is formed by an 
epithelium, which is one cell layer thick, and is composed of cylindrical cells and 
goblet cells which secrete mucus.  
 
 
1.4 Rectal absorption 
Insertion of a suppository into the rectum results in a chain of effects leading to 
the bioavailability of the drug. The sequence of events leading to drug 
absorption from the anorectal area can be represented as follows: 
 
Drug in vehicle  Drug in colon fluids  Absorption through the rectal mucosa  
 
To be available for absorption, drugs must be released from the suppository 
and distributed by the surrounding fluids to sites of absorption. Depending on 
the character of its vehicle a suppository will either dissolve in the rectal fluid 
(water-soluble bases) or melt on the mucous layer (fatty bases).  
 
Independent of the vehicle type, drugs that are dissolved in the suppository 
diffuse out towards the rectal membranes. On the other hand, the suspended 
drugs first leave the vehicle (if it is water immiscible) under the influence of 
gravity or motility movements, and then start to dissolve in the rectal fluid. The 
dissolved drug molecules diffuse through the mucous layer into the epithelium 
forming the rectal wall to be absorbed by the tissues and eventually transported 
into the general circulation (Chicco et al., 1999). The process of absorption is 
through passive diffusion throughout the whole GI tract for nearly all drugs.  
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Blood supply, especially veinous drainage, is important for the understanding of 
drug absorption. There is abundant vascularisation of the submucosal region of 
the rectum wall with blood and lymphatic vessels. A diagram of part of the rectal 
wall and the rectum veinous drainage is shown in Figure 1.1.  
 
As can be seen from the figure, there are three separate veins. Depending on 
the height at which absorption occurs in the rectum, the drug passes into the 
inferior, middle or superior haemorrhoidal veins. Inferior vein is nearest to the 
anus. The inferior and middle haemorrhoidal veins drain directly into the general 
circulation (via the inferior vena cava) and bypass the liver, while the superior 
haemorrhoidal vein drains into the hepatic portal vein which flows to liver. There 
are extensive anastomoses between the lower and upper hemorrhoidal veins 
(Ryu et al., 1999). The lymphatic circulation also helps in absorbing a rectally 
administered drug and in diverting the absorbed drug from the liver. This means 
that drug molecules can enter the general circulation directly or by passing the 
strongly metabolising liver. In the latter, only a proportion of the drug molecules 
(if they are of the high clearance type) enters the general circulation intact. Thus 
the bioavailability may be less than 100 %.  
 
 
 
 
 
 
 
 7 
 
 
          
 
 
         Figure 1.1: Veinous drainage of human rectum (Blaey and Tukker, 1988). 
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It was once believed that medicaments from suppositories were largely 
transported by the inferior and middle haemorrhoidal veins and therefore rectal 
administration of a drug provided a means of avoiding degradation of the drug 
by liver and damage of the liver by drug. Indeed, the liver modifies many drugs 
chemically and thereby often reduces their systemic effectiveness.   
 
However, it appears that suppositories have the tendency to migrate to the 
upper rectum after administration (Yahagi et al., 1999). In such cases, only drug 
released from suppositories and absorbed at the lower rectum could avoid first-
pass effect and retain their therapeutic values (Coben and Liebermann, 1986; 
Chicco et al., 1999). Hence, keeping the drug in lower part of the rectum is 
strongly advisable, specifically if the suppository is retained in the bottom one-
third of the rectal vault (Hosny et al., 1995; Hosny et al., 1996a). 
 
 
1.5 Factors influencing rectal absorption 
The rate-limiting steps in suppository drug absorption are the partitioning of the 
dissolved drug from the melted base (Coben and Liebermann, 1986) and 
diffusion of the drug to the site on the rectal mucosa where absorption occurs 
(Moolenaar and Schoonen, 1980). The factors influencing rectal drug 
absorption are as follows:  
 
1. Quantity of fluid available 
Partitioning between base and rectal fluid is affected by the varied volume of 
water in the rectum. This volume is very small and varies among individuals 
at different time (Blaey and Tukker, 1988). Only under non-physiological 
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circumstances is this volume enlarged, such as through osmotic attraction 
by water-soluble vehicles or diarrhoea.  
 
2. Properties of the rectal mucous 
Properties of rectal fluid, such as composition, viscosity and surface tension 
are unknown. The mucous blanket acts as a mechanical barrier for free 
passage of drug through the pore space for absorption (Coben and 
Liebermann, 1986). 
 
3. Rectal pH 
The pH of the rectal mucosa plays a significant rate-controlling role in drug 
absorption (Ansel, 1981). The principal method of drug absorption is 
diffusion through lipid regions of cell membranes and therefore unionised 
drugs (which are more soluble in lipids than the ionised forms) are absorbed 
more readily. The completely ionised drugs and unionised substances which 
are lipid-insoluble are also poorly absorbed. The state of ionisation of drug 
depends on the environmental pH. Rectal fluids are essentially neutral in pH 
and have virtually no buffer capacity. As a consequence, the dissolving 
drugs may influence the pH existing in the anorectal area. The weaker acids 
and bases are more readily absorbed than the stronger, highly ionised ones 
(Coben and Liebermann, 1986). It seems that the anorectal and colonic 
mucosa are selectively permeable to the uncharged drug molecule. 
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4. Contents of rectum 
The rectum is usually empty except when fecal matter arrives from higher 
part of the colon temporarily. This material is either expelled or transported 
back into colon, depending on the voluntary control exhibited by the anus 
sphincter. A drug has greater opportunity to make contact with the absorbing 
rectal surface in the absence of fecal matter. Other conditions such as 
diarrhoea, colonic obstruction and tissue dehydration can influence the rate 
and degree of drug absorption from the rectal site (Ansel, 1981).  
 
5. Motility of the rectal wall 
The rectal wall may exert a pressure on a suppository present in the lumen 
by two distinct mechanisms (Ansel, 1981). The abdominal organs that simply 
press on to the rectum, especially when the body is upright may stimulate 
spreading and promote absorption. The second source of pressure is the 
motility of the rectal wall muscles originated from the normally occurring 
colonic motor complexes. These are waves of contractions running over the 
wall of the colon in caudal direction and are associated with the presence of 
food residues in the colon. 
 
6. Partition coefficient of drug 
Drug solubility in rectal fluid determines the maximum attainable 
concentration and thus the driving force for absorption. When a drug has 
high vehicle to water partition coefficient, the tendency to leave the vehicle is 
small and thus the release rate into the rectal fluid is low. This is 
unfavourable for rapid absorption. On the other hand, a certain lipid solubility 
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is required for penetration through the rectal membrane. The optimal 
balance between these two requirements is usually found using the rules 
listed in Table 1.1 (Blaey and Tukker, 1988). 
 
Table 1.1: Drug solubility and suppository formulation. 
 Drug solubility 
Fat Water 
Choice of base 
Low High Fatty base (Rule 1) 
High Low Aqueous base (Rule 2) 
Low Low Indeterminate 
 
 
Assuming that the release from the dosage form is considered as the rate-
limiting step, the tendency to remain in the base should be lowered as much 
as possible (Rules 1 and 2). When the solubility in fat and water are both low 
no definite rule can be given.  
 
7. Drug particle size 
The absorption of a drug in suspension is limited by its dissolution rate. 
Therefore, when a drug is formulated in the suppository as suspension in the 
undissolved state, it is advantageous to use fine powder to increase surface 
area and enhance dissolution (Blaey and Tukker, 1988). This is particularly 
relevant to rectal dosage forms because the rectum lacks the large surface 
area and considerable movement of contents that aid absorption in the gut.  
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8. Nature of base  
If the suppository base interacts with the drug inhibiting its release, drug 
absorption will be impaired or even prevented. Also, if the base is irritating to 
the mucous membranes of the rectum, it may initiate a colonic response and 
prompt a bowel movement, negating the prospect of a thorough drug 
release and absorption (Ansel, 1981).  
 
9. Presence of additives in base 
Emulsifying agents such as wax, wool fat, wool alcohols and polysorbates 
may be included in suppository bases to facilitate incorporation of aqueous 
solutions or polar liquids, but they should be used with caution as their 
effects on release and absorption are unpredictable. The inclusion of a 
powerful surface-active agent may greatly increase absorption of a drug but 
with subsequent toxic effects. 
 
 
1.6 Suppository bases  
Suppository bases play an important role in the release of the medication they 
hold and therefore in the availability and absorption of drug for systemic or 
localised effects (Ibrahim et al., 1990). Generally, suppository bases fall into two 
categories; fatty bases that melt at body temperature and water-soluble or 
water-miscible bases that dissolve or disperse in rectal secretions.  
 
The ideal suppository base (Carter, 1975; Coben and Liebermann, 1986) 
should melt at body temperature or dissolve and disperse in body fluids, release 
any medicament readily, able to keep its shape while being handled, completely 
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non-toxic and non-irritant to sensitive and inflamed tissues, non-sensitising, has 
no metastable forms and stable on storage, such as does not change colour, 
odour or drug release pattern. It should have wetting and emulsifying properties, 
stable if heated above its melting point and shrinks sufficiently on cooling to 
release itself from the mould without the need for mould lubricants. The base 
should also possess a high ‘water number’, namely a high percentage of water 
that can be incorporated in it. Last but not least, the suppository base should be 
esthetically acceptable and mouldable by hand, machine, extrusion or cold 
compression. 
 
A suppository base containing all these properties is not yet found (Carter, 
1975). Indeed, some of the properties are mutually exclusive and not ideal in all 
situations. Often, the addition of drugs changes the desirable characteristics of 
the base.  
 
 
1.6.1 Fatty bases 
1.6.1 (a)  Theobroma Oil (Cocoa Butter) 
Cocoa Butter USP (CB) is defined as the fat obtained from the roasted seed of 
theobroma cocoa. This oleaginous base is a classic suppository vehicle, having 
been used for over 200 years. It is yellowish-white solid, brittle fat with a 
chocolate-like odour that melts to form non-viscous, bland oil and has an 
emollient or soothing action.  
 
CB has several disadvantages. It can become rancid due to oxidation of the 
unsaturated glycerides, melt in warm weather and liquefy when incorporated 
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with certain drugs. CB does not contain emulsifiers and therefore does not take 
up large quantities of water. As CB can easily melt and become rancid, it must 
be stored in cool, dry place and be protected from light.  
 
CB exhibits marked polymorphism (the ability to exist in different crystalline 
forms, namely α, β, β’ and γ with melting points of 22, 34, 28 and 18 oC 
respectively), a phenomenon probably attributed to the high proportion of 
unsaturated triglycerides. The most stable β form is preferable for suppositories. 
The formation of the various crystalline forms depends on the conditions and 
degree of heating and cooling. Prolonged heating above 36 oC causes the 
formation of the unstable crystal with lower melting points. The conversion to 
the stable β form takes 1 to 14 days, depending on the storage temperature – 
the higher the temperature, the faster the change. As a general rule, minimal 
use of heating in the process of melting the fat is recommended.  
 
 
1.6.1 (b)  Cocoa Butter Substitutes (CBS) or Cocoa Butter replacers (CBR) 
CBS or CBR are terms used for the almost exclusively semi- or fully synthetic 
fatty vehicles in use nowadays. The disadvantages inherent to CB have 
prompted a search for more superior substitutes. The satisfactory bases 
maintain the many desirable properties of CB, and attempts are made to 
eliminate the objectionable properties.  
 
The general composition of CBS is derived from hydrogenated cottonseed oil, 
palm oil, palm kernel oil and coconut oil, with self-emulsifying and suspending 
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agents (Allen, 1995). Hydrogenated palm kernel oil was recommended as a 
suppository base as early as 1939 by Caldwell (Carter, 1975).  
 
Palm kernel oil is produced from the center kernel of the Elaeis guineensis 
palm. By optimising the fractionation and hydrogenation conditions, several 
grades of palm mid-fractions with different solid fat content and melting 
characteristics can be produced (Malaysian Palm Oil, 1995). Palm oil and palm 
kernel oil are consumed worldwide as cooking oil, in margarines and 
shortening, and as ingredient in fat blends and a vast array of food products.  
 
Most manufacturers market a series of CBS grades with slightly different 
melting point ranges and degree of hardness. CBS is generally stable with a low 
irritation profile, need no special storage condition, uniform in composition, and 
has bland taste with controlled melting range. Their solidifying points are 
unaffected by overheating.  
 
CBS bases also have good resistance against oxidation due to their reduced 
unsaturated fatty acids. Their acid value is low (almost < 0.5 compared to > 4 
for CB) that accounts for the slower ageing of suppositories in semi-synthetic 
vehicles. CBS also exhibits excellent mould release characteristics and do not 
require mould lubrication. The emulsifying and water-absorbing capacities of 
CBS are good as they usually contain a proportion of partial glycerides, such as 
glyceryl monostearate which are water/oil emulsifying agents. CBS is opaque-
white, almost odourless and has very attractive, clean, polished appearance. 
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The difference between melting and setting points in CBS is small; generally 
only 1.5 to 2 oC. Hence, they set quickly. The risk of sedimentation is low, and 
they are easier to administer. When the setting point of base is well below the 
melting point, the suppositories soften quickly when handled and become too 
slippery to administer. 
 
However, precaution should be taken not to cool CBS too quickly lest they 
become brittle. They are also more fluid than CB when melted and at this stage 
sedimentation is greater. Thickeners, such as magnesium stearate, bentonite 
and colloidal silicon dioxide, may be added to counter such problems. 
 
 
1.6.1 (c)  Witepsol 
Witepsol comes in different grades, all nearly white and almost odorless. These 
bases solidify rapidly in the mould, and lubrication is not necessary as the 
suppositories contract nicely. Witepsol will absorb limited quantities of water 
since these bases contain emulsifiers.  
 
 
1.6.2  Water soluble bases  
1.6.2 (a) Polyethylene glycol (PEG) 
PEG (also known as macrogol) is widely used as a water soluble suppository 
base. They are mixtures of PEGs of different molecular weights (MWs). The 
more commonly used being PEG 200, 400, 600, 1000, 1500, 1540, 3350, 4000 
and 6000. The numerical designation refers to the average MW of each 
polymer.  
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The PEG bases generally have a melting point above 42 oC. Hence, cold 
storage is not required, they are satisfactory for use in hot climates, and 
administration is easy because they are not slippery to handle. Their physical 
properties can be varied by suitable mixture of high and low MW polymers. High 
MW polymers give hard products that disintegrate and release drug slowly. 
Softer and less brittle suppositories that liberate drug more quickly are obtained 
by mixing high with either medium or low MW polymers.  
 
PEG bases do not melt but gradually dissolve and disperse in the body, freeing 
medication slowly and providing longer action than fatty bases. PEG 
suppositories have smooth appearance, absorb water and do not leak from the 
anus as do many fatty suppositories. They also absorb water and have 
excellent solvent properties. Unlike glycerol-gelatin bases, PEGs do not stick to 
the mould since they contract significantly on cooling and moreover no lubricant 
is required. 
 
However, PEG suppositories are hygroscopic and therefore attract water, 
resulting in painful sensation for patients. They may produce slight dehydration 
of the rectal mucosa as they take up water to dissolve. Furthermore, a 
considerable number of incompatibilities with various drugs, such as phenols 
and sulphonamides have also been reported (Allen, 1995). The solubilising 
character of this base (low dielectric constant) can result in the retention of the 
drug in the liquefied base with reduction in therapeutic activity. PEG 
suppositories sometimes fracture and exhibited crystal growth on storage, 
particularly if they contain water. One cause is the high solubility of PEGs which 
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can lead to a supersaturation in water and subsequent crystallisation which 
makes the mass granular and brittle. 
 
In practice, PEGs have been found to be valuable for drugs which are 
practically insoluble in water (diazepam, indomethacin) and where solubility can 
be improved by the presence of water soluble vehicles (Moolenaar and 
Schoonen, 1980). 
 
 
1.6.2 (b)  Glycerinated gelatin base 
Glycerinated gelatin suppositories which are composed of glycerin (70 %), 
gelatin (20 %), and water (10 %), should be packaged in air tight containers 
since they are hygroscopic. They are not recommended as rectal suppository 
base because they may exert an osmotic effect and a defecation reflex. A 
glycerin base is composed of glycerin (87 %), sodium stearate (8 %) and water 
(5 %). These bases have occasionally been used for the preparation of 
pessaries. 
 
The most commonly used suppository bases are listed in Table 1.2.
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1.7 Bioadhesives 
Generally, bioadhesive is defined as synthetic or natural substance that is 
capable of adhering or interacting with biological materials and able to be 
retained on the biological surface and retard natural clearance processes for an 
extended period of time (Hassan and Gallo, 1990; Mortazavi, 1995; Prudat-
Christiaens et al., 1996; Lee et al., 2000; Singla et al., 2000). Specifically, 
mucoadhesives are polymers which interact primarily with the mucus layer 
covering the mucosal epithelial surface and mucin molecules that constitute a 
major part of mucus (Smart, 1991; Ahuja et al., 1997).  
 
The goal of the development of bioadhesive is to mimic or improve biological 
adhesives (Ahuja et al., 1997). The majority of bioadhesive polymers studied for 
drug delivery adhere to epithelial tissues and perhaps to the mucus coat 
present on the surface of these tissues. Mucus-coated tissue is found in most 
nonparenteral routes of administration (Mortazavi et al., 1993). Target sites for 
bioadhesive drug delivery include the eye (Saettone et al., 1999), buccal (Wong 
et al., 1999a), peroral, nasal (Nagai and Machida, 1985), vaginal (Ceshel et al., 
2001), GI tract (Ch’ng et al., 1985), rectal (Hosny et al., 1995; Hosny et al., 
1996a) and cervical (Nagai and Machida, 1985).  
 
Bioadhesive force in the rectal delivery system denotes the force and strength 
with which suppositories bind to rectal lining at 36.5 oC (Choi et al., 1998a,b; 
Kim et al., 1998; Choi et al., 1999). Rectal mucous lining consists of 
oligosaccharide chains with sialic acid. Hence, polymers with macromolecules 
hydrocolloids containing numerous hydrogen bond forming groups can bind 
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strongly to oligosaccharide chains, resulting in strong bioadhesive force (Kim et 
al., 1998).  
 
 
1.8 Advantages of rectal bioadhesion 
1. Increasing the residence time of dosage form 
Localising suppository in the rectum may help to prevent it from moving 
upwards, reaching the end of colon, which is the pathway for first-pass 
effect. In other words, it is an attempt to restrict drug absorption from 
suppositories at the lower rectum. Drug absorbed in this region enter directly 
into the systemic circulation resulting in increased systemic availability and 
improvement in the therapeutic efficacy due to avoidance of first-pass 
elimination (Yahagi et al., 2000).  
 
2. Higher drug concentration in a local area 
Retaining the suppository may also provide intimate contact of dosage form 
with the absorbing tissue for an extended period of time (Ahuja et al., 1997). 
This may produce a steep concentration gradient in the local area and 
hence, higher drug flux through the absorbing tissue favoring drug 
absorption (Hosny et al., 1995; Hosny and Al-Angary, 1995).  Furthermore, 
the intimate contact has been proven to increase the permeability of the 
epithelial tissues towards high molecular weight drugs such as peptides and 
proteins (Hosny et al., 1996a).  
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1.9 Bioadhesive polymers 
Most bioadhesives are based on polymers that differ in the degree of erodibility, 
swelling and sensitivity to the biological environment. They are generally 
hydrophilic macromolecules or hydrocolloids that contain anionic charges and 
strong hydrogen bond forming groups (hydroxyl, oxide and carboxyl groups) 
with high molecular weight, sufficient chain flexibility and surface energy 
properties favoring spreading onto mucus (Lehr et al., 1992).  
 
The ideal bioadhesives would be site-specific, durable when required, 
biodegradable when necessary, non-irritant to the mucous membrane, non-toxic 
and non-absorbable from the GI tract (Ceshel et al., 2001), preferably form a 
strong non-covalent bond with the mucin-epithelial cell surfaces, adhere quickly 
to moist tissue (Smart, 1991; Mortazavi et al., 1993; Singla et al., 2000), allow 
easy incorporation of the drug and offer no hindrance to its release, be cost 
productive and should not decompose on storage or during the shelf-life of the 
dosage form.  
 
The water-soluble polymers are typically linear or random hydrophilic polymers 
(e.g. polyacrilic acid, PAA). The water-insoluble types are commonly called 
hydrogels (Rao and Devi, 1988). They are swellable network formed by 
covalent or ionic bonds via a cross-linking agent (e.g. polycarbophil, PCP). The 
swellable polymers have the ability to release entrapped drugs in aqueous 
medium and the release of such drug can be regulated by the control of 
swelling and degree of cross-linking (Bravo et al., 2002).  
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In the case of water-soluble polymers, the duration of residence time on tissue 
surfaces is based on dissolution rate of the polymer. In contrast, cross-linked 
polymers, given their lack of solubility in common solvents, have a residence 
time based on the rate of mucus/tissue turnover. 
 
Most of the current synthetic bioadhesive polymers are either PAA or cellulose 
derivatives.   Examples   of   PAA-based   polymers   are   Carbopol   (CP), 
polycarbophil (PCP), polyacrylate, poly(isohexylcyanoacrylate) and 
poly(isobutylcyanoacrylate).  
 
Cellulose ethers are becoming popular as matrices since they are easy to 
prepare, can accommodate a large percentage of drug and the release is less 
influenced by the processing variables (Rao and Devi, 1988). Chemically, 
cellulosic polymers share a common cellulosic backbone, but they have 
different substituent groups, which may be ionic or non-ionic.  
 
These linear polymers are produced by partial or total etherification of the 3 
hydroxyl groups present on the anhydroglucose repeat unit of the cellulose 
chain. Following the addition to an aqueous phase, the cellulose derivatives 
undergo swelling prior to dissolution (Jones et al., 1997). Cellulosic polymers 
include carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC), 
hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (NaCMC), 
methyl cellulose (MC) and methylhydroxyethyl cellulose (MHEC). 
 
In addition, poly(N-2-hydroxypropyl methacrylamide) (PHPMAm), 
polyvinylpyrrolidone (PVP) and poly(vinylalcohol) (PVA) can also be included as 
